No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GPCR240816P32500
- 1.15
- -0.10-8.00%
15min DelayClose Jul 22 15:59 ET
1.15High1.15Low
1.15Open1.25Pre Close1 Volume10 Open Interest32.50Strike Price115.00Turnover76.50%IV14.32%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry1.15Extrinsic Value100Contract SizeAmericanOptions Type-0.2397Delta0.0423Gamma31.82Leverage Ratio-0.0444Theta-0.0062Rho-7.63Eff Leverage0.0298Vega
Intraday
- 5D
- Daily
News
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Piper Sandler analyst Yasmeen Rahimi maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate
Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ
By David Wainer The two dominant players in the obesity market will eventually make way for a few more competitors. Just don't expect the latecomers to be equals to Eli Lilly and Novo Nordisk. There
Express News | Shares of Weight Loss Stocks Are Trading Lower, Possibly on Continued Weakness Following Recent Weight Loss Data From Roche, Which Could Cause Competition Concerns for Companies in the Space
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for
Express News | Structure Therapeutics Shares Are Trading Lower Following Weight Loss Data From Competitor Roche
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday.What happened?
Comments
$ROCHE HOLDING AG(RHHBY.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
5
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
It seems that they will be going for acquisition of easy to manufacture weight loss pills $Structure Therapeutics(GPCR.US$
News offering dropped🤢 ❗️❗️❗️**FOR IMMEDIATE RELEASE** Globe wire newsletter June 3,2024 2:57 pm est
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
1
Read more